CompletedNot Applicable

Nicotinamide Riboside and Metabolic Health

Netherlands15 participantsStarted 2016-12

Plain-language summary

This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepatic and whole body insulin sensitivity. Secondary objectives, to provide information about the underlying mechanism, will be muscle mitochondrial function, brown fat activity, ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body composition and acetylcarnitine levels.

Who can participate

Age range45 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent * Caucasian * Males and postmenopausal females * Aged 45-65 years at start of the study * Body mass index (BMI) 27 - 35 kg/m2 * Stable dietary habits (no weight loss or gain \>5kg in the past 3 months) * Sedentary lifestyle (not more than 2 hours of sports per week) Exclusion Criteria: * Type 2 diabetes * Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) * Contra-indication for MRI * Participation in earlier research or medical examination that included PET/CT scanning * Alcohol consumption of \>2 servings per day * Smoking in the past 6 months

What they're measuring

Insulin sensitivity: muscle- and liver specific

Timeframe: 6 weeks after supplementation

Trial details

NCT IDNCT02835664

SponsorMaastricht University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

View on ClinicalTrials.gov More Obesity trials